Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Zevra Therapeutics logo

About Zevra Therapeutics Stock (NASDAQ:KMPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Remove Ads
Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
[Revealed] Trump’s Plan to Protect Your Savings for the Deep State
During Trump's first term, gold skyrocketed 52.89%. And it's already surging before his second. Last year, gold crushed the S&P—27% vs. 23%—and hit 30 record highs.
Zevra Therapeutics reports Q4 EPS (67c), consensus (40c)
Zevra Therapeutics to sell Rare Pediatric Disease PRV for $150M
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM
Zevra Therapeutics price target raised to $21 from $20 at Guggenheim
See More Headlines

KMPH Stock Analysis - Frequently Asked Questions

Zevra Therapeutics, Inc. (NASDAQ:KMPH) released its quarterly earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

Zevra Therapeutics (KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Video Communications (ZM) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
3/30/2022
Today
3/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Price / Cash Flow
23.28
Book Value
$3.63 per share
Price / Book
N/A

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:KMPH) was last updated on 3/16/2025 by MarketBeat.com Staff
From Our Partners